Revascularization therapies for acute stroke patients aim to rescue the ischemic penumbra by restoring the patency of the occluded artery (“recanalization”) and the downstream capillary blood flow (“reperfusion”). This article reviews the definition of recanalization and reperfusion used in stroke clinical trials and their limitations and proposes a study design to determine the relative importance of recanalization, reperfusion, and collateral flow in evaluating the efficacy of revascularization therapies for acute ischemic stroke. (Stroke. 2009;40[suppl 1]:S24-S27.)

Key Words: brain infarction  ■  brain ischemia  ■  cerebral infarct  ■  CT  ■  magnetic resonance  ■  neuroradiology  ■  reperfusion  ■  tPA

From an imaging standpoint, treatment efficiency can be, and has been, evaluated at different levels: (1) restoration of the patency of the primary arterial occlusion; (2) assessment of the patency of the main branches distal to the occlusion, to take into account that the primary clot can break into fragments that can migrate and occlude branches downstream from the primary occlusive lesion (Figure 1A); (3) evaluation of the entry and clearance rate (“wash-in” and “wash-out”) of antegrade flow in distal branches (Figure 1B), to take into account the no-reflow phenomenon; (4) capillary perfusion blood flow, which goes beyond the angiographic assessment of contrast wash-in and wash-out, because it has the ability to quantitatively estimate the hemodynamic specifics of focal ischemia on the brain parenchyma (Figure 1C). The no-reflow phenomenon, first described in 1967 in the context of cerebral ischemia, is defined as inadequate perfusion through a vascular segment without evidence of persistent mechanical obstruction. The underlying pathophysiology of this phenomenon is debated, but it is generally accepted that no-flow is associated with higher complication rates.

The terms recanalization and reperfusion are often used interchangeably in acute stroke literature, although they refer to different concepts, which complicates the comparison of efficiency among studies. Indeed, different scoring systems using different imaging techniques have been used to assess one, or several, of the levels listed above (Table). Adding to the confusion, the same name has been attributed to scoring systems looking at varying end points (Table). For instance, the Thrombolysis in Myocardial Infarction (TIMI) score, created in 1985 using conventional angiography to report the efficacy of myocardial reperfusion therapy, evaluates the wash-in and wash-out of contrast from the distal coronary capillary bed; the degree of patency of the primary occlusive lesion is not included in the original TIMI score. Higashida et al proposed the Thrombolysis in Cerebral Infarction (TICI) score, and adapted the original TIMI score for the cerebral circulation as assessed on conventional angiography (Figure 1A). In the DIAS and DEDAS trials, a modified TIMI score was used, exclusively addressing the primary arterial occlusion on static MRA imaging, and defining reperfusion as a 2 points or greater improvement on this grading scheme. Efficacy end points also included 30% or more reduction of volume of abnormality on PWI mean transit time maps. The DEFUSE study focused solely on capillary perfusion blood flow, requiring 30% or greater and 10 mL or more reduction in PWI lesion volume (using as threshold a 2-second delay on Tmax maps) on the follow-up MR scan done between 3 and 6 hours to characterize reperfusion. Subsequently, in EPITHET trial, a distinction was made between recanalization and reperfusion as end points. The same MRA-based definition that was applied in DIAS and DEDAS trials (but named reperfusion on those trials) was used this time to characterize recanalization, whereas the criteria for reperfusion required 90% or more reduction in the volume of PWI abnormality (Tmax delay of 2 s or more, same as in DEFUSE) between baseline and day 3 MR studies.

A comprehensive review addressing the inconsistencies in terminology, definition, and application of recanalization/reperfusion scores has been previously provided.

Which Score Is Clinically Relevant?
The MERCI and PENUMBRA devices received FDA 510(k) clearance based on their demonstrated ability to recanalize...
the primary occlusive arterial lesion without considering the status of arterial branches distal to the treated vessel. However, as stated previously, recanalization of the primary occlusive arterial lesion does not necessarily imply capillary reperfusion.

Also, lack of recanalization does not necessarily reflect absence of reperfusion. Among 57 patients who did not achieve recanalization on the DIAS trial, 24.6% achieved favorable clinical outcome after 90 days (defined as 8 or more points improvement on NIHSS [or 0 to 1], mRS [0 to 2], and...
BI [75 to 100]), suggesting that reperfusion can occur in the absence of recanalization. One possible explanation is retrograde collateral flow. Adequate collateral circulation may contribute to maintain tissue viability in the absence of complete recanalization. Collateral flow is currently best evaluated on dynamic angiography, though reliable static scoring systems have been proposed to measure collateral flow on CTA.

**Next Steps and Conclusion**

The hypothesis—restoration of capillary perfusion and adequate collateral flow results in smaller infarct size and better clinical outcome, whereas lack of reperfusion coupled with poor collateral flow results in larger infarct and worse clinical outcome (Figure 2)—remains to be definitively validated. One possible design would be to systematically evaluate the four different levels of vascular compromise listed above, both before and after revascularization treatment, in a prospective series of acute stroke patients. Arterial patency/flow restoration at these levels, as well as the degree of collateral flow, would serve as predictors. This would be correlated with standard clinical and imaging end points, such as final infarct volume. This design would allow determination of the relative importance of recanalization, reperfusion, and collateral flow in evaluating the efficacy of revascularization therapies for acute ischemic stroke.

**Sources of Funding**

M.W. received funding from the National Center for Research Resources, grant KL2 RR024130.

**Disclosures**

None.

**References**


MR and CT Monitoring of Recanalization, Reperfusion, and Penumbra Salvage: Everything That Recanalizes Does Not Necessarily Reperfuse!
Bruno P. Soares, Jeffrey D. Chien and Max Wintermark

Stroke. 2009;40:S24-S27; originally published online December 8, 2008; doi: 10.1161/STROKEAHA.108.526814

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/40/3_suppl_1/S24

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org/subscriptions/